BHIVA rapid guidance on the use of statins for primary prevention of cardiovascular disease in people living with HIV
November 21, 2023
In cohort studies, compared to the general population or controls without HIV, people living with HIV are at greater risk of atherosclerotic cardiovascular disease (CVD). There are established national guidelines for the primary prevention of CVD with statins. Because general population CVD risk calculators may underestimate risk in people living with HIV, HIV is considered an additional CVD risk factor, but there are no specific recommendations for people living with HIV. REPRIEVE, the largest randomised trial undertaken in people living with HIV, demonstrated a significant reduction in major adverse cardiovascular events in participants randomly assigned to pitavastatin 4 mg daily as compared to those receiving placebo. Here we provide rapid guidance on the implications of the REPRIEVE study for clinical practice.